Study Comparing One Daily Beam Versus Two Daily Beams of Proton Therapy for Treating Bone and Soft Tissue Tumors Including Chordoma, Chondrosarcoma, Ewing Sarcoma, and Osteosarcoma

What this Trial Is About

Researchers are evaluating proton therapy in patients with chordoma, chondrosarcoma, Ewing sarcoma, and osteosarcoma who require two radiation beams for treatment. This study aims to compare the toxicity of proton therapy delivered using a single daily beam versus the conventional approach of two daily beams. The latest ProteusOne proton therapy equipment with a compact rotating gantry enables precise targeting of tumors from different angles, potentially reducing treatment side effects. Participants are randomly assigned to receive either one daily beam, which delivers a doubled dose in each session, or two daily beams delivered according to the standard treatment plan. Both beams are conventionally delivered in the same session but require repositioning the patient before each beam, which takes extra time. This study evaluates whether delivering only one beam daily can maintain treatment effectiveness while reducing toxicity and saving time over the 2 to 7 week treatment period. During the treatment and up to five years of follow-up, patients will be monitored for side effects, quality of life, and treatment effectiveness. Researchers will measure the frequency of toxicities and assess quality of life throughout treatment and follow-up. They will also evaluate the time saved by using a single daily beam. The total participant involvement includes initial treatment and long-term follow-up visits to assess outcomes and safety.

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy